Global Veterinary Vaccines Market - 2024-2033

March 2026 | 243 pages | ID: G348B9BEEE50EN
DataM Intelligence

Abstracts

The Global Veterinary Vaccines Market was valued at US$ 11.5 Billion in 2024 and is anticipated to reach US$ 23.4 Billion by 2033, at a CAGR of 0.082 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Veterinary Vaccines Market.

This report delivers a comprehensive overview of the Global Veterinary Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Veterinary Vaccines Market. The Global Veterinary Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Global Veterinary Vaccines Market Scope:

By Animal Type

• Livestock
• Companion
• Aquaculture Vaccines
• Others

By Product

• Traditional Vaccines
• Advanced Vaccines

By Route of Administration

• Subcutaneous
• Intramuscular
• Oral
• Intranasal
• Intraocular
• Others

By End User

• Veterinary Hospitals
• Veterinary Clinics
• Retail Pharmacies
• E-commerce
• Others

By Disease Indication

• Foot-and-Mouth Disease (FMD)
• Newcastle
• Porcine Reproductive and Respiratory Syndrome
• Avian Influenza
• Canine Parvovirus
• Brucellosis
• Rabies
• Others

Key Players

• Merck & Co., Inc.
• Zoetis Services LLC
• Ceva.
• Boehringer Ingelheim International GmbH
• Elanco
• Virbac
• Biogenesis Bago
• Neogen Corporation
• Bimeda Biologicals

Major Highlights

This report delivers a comprehensive overview of the Global Veterinary Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Veterinary Vaccines Market. The Global Veterinary Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period

2. EXECUTIVE SUMMARY

2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Increasing prevalence of zoonotic and livestock diseases driving demand for preventive vaccination
    3.1.1.2. Rising threat of zoonotic disease transmission between animals and humans, accelerating preventive vaccination adoption
    3.1.1.3. Increasing investments in advanced veterinary biologicals, including recombinant and vector-based vaccines
  3.1.2. Restraints
    3.1.2.1. Complex cold-chain and storage requirements limiting vaccine accessibility in rural livestock regions
    3.1.2.2. Variability in vaccination compliance among small-scale livestock farmers affecting market penetration
  3.1.3. Opportunity
    3.1.3.1. Advancements in biotechnology enabling development of recombinant and next-generation biological vaccines
    3.1.3.2. Expansion of vaccination programs in emerging markets with growing livestock populations
  3.1.4. Trends
    3.1.4.1. Increasing adoption of recombinant and genetically engineered veterinary vaccines
    3.1.4.2. Growing focus on disease prevention strategies to reduce antimicrobial resistance in animal health
  3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Global Veterinary Vaccines Market
4.2. Geopolitical & Supply Chain Exposure
  4.2.1. Biological raw material sourcing and antigen supply concentration
  4.2.2. Trade policies, animal health regulations, and livestock disease outbreak risks
4.3. Social & Animal Health Factors
  4.3.1. Veterinarian vaccination recommendations and livestock health management practices
  4.3.2. Livestock farmer adoption and compliance with vaccination programs
  4.3.3. Increasing companion animal healthcare awareness
  4.3.4. Growing focus on zoonotic disease prevention and animal welfare
4.4. Economic Factors
  4.4.1. Rising investment in animal healthcare infrastructure
  4.4.2. Cost sensitivity among livestock producers and vaccination program budgets
4.5. Pricing Analysis
  4.5.1. Branded biological vaccines vs generic veterinary vaccine pricing dynamics
4.6. Regulatory Analysis
  4.6.1. Veterinary vaccine approval pathways and regulatory requirements
  4.6.2. Post-market surveillance and veterinary pharmacovigilance
  4.6.3. GMP compliance and quality control in biological vaccine manufacturing
  4.6.4. Regional regulatory authorities and harmonization across global markets
4.7. Go-To-Market (GTM) Strategy
  4.7.1. Veterinary hospitals, livestock farms, and agricultural distribution networks
4.8. Innovation & R&D Trends
  4.8.1. Development of recombinant and next-generation biological vaccines
  4.8.2. Increasing focus on multivalent and combination veterinary vaccines
4.9. Sustainability and ESG Analysis
  4.9.1. Responsible biological material sourcing and sustainable livestock disease management
4.10. Veterinary Vaccine Ecosystem Participants
  4.10.1. Veterinary vaccine manufacturers
  4.10.2. Biotechnology and biological research companies
  4.10.3. Veterinary distributors and animal health service providers
  4.10.4. Contract manufacturing organizations for biological products
  4.10.5. Livestock producers and veterinary healthcare providers
4.11. Buyer Decision Criteria & Adoption Drivers
  4.11.1. Vaccine efficacy and disease prevention effectiveness
  4.11.2. Regulatory approval and safety profile
  4.11.3. Cost-effectiveness and vaccination program scalability
  4.11.4. Availability across livestock and companion animal disease segments
4.12. DMI Opinion – Strategic Outlook for the Global Veterinary Vaccines Market

5. BY ANIMAL TYPE

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  5.1.2. Market Attractiveness Index, By Animal Type
5.2. Livestock *
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  5.2.3. Cattle
  5.2.4. Swine
  5.2.5. Poultry
  5.2.6. Others
5.3. Companion
  5.3.1. Canine
  5.3.2. Feline
5.4. Aquaculture Vaccines
5.5. Others

6. BY PRODUCT

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  6.1.2. Market Attractiveness Index, By Product
6.2. Traditional Vaccines*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  6.2.3. Live Attenuated
  6.2.4. Inactivated / Killed
  6.2.5. Toxoid
6.3. Advanced Vaccines
  6.3.1. Recombinant
  6.3.2. Subunit and Conjugate
  6.3.3. Vector-Based
  6.3.4. Nucleic Acid
    6.3.4.1. DNA
    6.3.4.2. mRNA

7. BY ROUTE OF ADMINISTRATION

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Subcutaneous*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intramuscular
7.4. Oral
7.5. Intranasal
7.6. Intraocular
7.7. Others

8. BY END USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  8.1.2. Market Attractiveness Index, By End User
8.2. Veterinary Hospitals*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Veterinary Clinics
8.4. Retail Pharmacies
8.5. E-commerce
8.6. Others

9. BY DISEASE INDICATION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  9.1.2. Market Attractiveness Index, By Disease Indication
9.2. Foot-and-Mouth Disease (FMD)*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Newcastle
9.4. Porcine Reproductive and Respiratory Syndrome
9.5. Avian Influenza
9.6. Canine Parvovirus
9.7. Brucellosis
9.8. Rabies
9.9. Others

10. BY REGION

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  10.1.2. Market Attractiveness Index, By Region
10.2. North America
  10.2.1. Introduction
  10.2.2. Key Region-Specific Dynamics
  10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.2.8.1. US
    10.2.8.2. Canada
    10.2.8.3. Mexico
10.3. Europe
  10.3.1. Introduction
  10.3.2. Key Region-Specific Dynamics
  10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.3.8.1. Germany
    10.3.8.2. United Kingdom
    10.3.8.3. France
    10.3.8.4. Italy
    10.3.8.5. Spain
    10.3.8.6. Netherlands
    10.3.8.7. Switzerland
    10.3.8.8. Sweden
    10.3.8.9. Norway
    10.3.8.10. Denmark
    10.3.8.11. Belgium
    10.3.8.12. Poland
    10.3.8.13. Austria
    10.3.8.14. Ireland
    10.3.8.15. Portugal
    10.3.8.16. Greece
    10.3.8.17. Finland
    10.3.8.18. Rest of Europe
10.4. Latin America
  10.4.1. Introduction
  10.4.2. Key Region-Specific Dynamics
  10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.4.8.1. Brazil
    10.4.8.2. Argentina
    10.4.8.3. Mexico
    10.4.8.4. Chile
    10.4.8.5. Colombia
    10.4.8.6. Peru
    10.4.8.7. Rest of Latin America
10.5. Asia-Pacific
  10.5.1. Introduction
  10.5.2. Key Region-Specific Dynamics
  10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.5.8.1. China
    10.5.8.2. Japan
    10.5.8.3. India
    10.5.8.4. South Korea
    10.5.8.5. Australia
    10.5.8.6. New Zealand
    10.5.8.7. Singapore
    10.5.8.8. Malaysia
    10.5.8.9. Thailand
    10.5.8.10. Indonesia
    10.5.8.11. Vietnam
    10.5.8.12. Philippines
    10.5.8.13. Taiwan
    10.5.8.14. Rest of Asia Pacific
10.6. Middle East and Africa
  10.6.1. Introduction
  10.6.2. Key Region-Specific Dynamics
  10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
  10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
  10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    10.6.8.1. Saudi Arabia
    10.6.8.2. United Arab Emirates
    10.6.8.3. Qatar
    10.6.8.4. Kuwait
    10.6.8.5. Oman
    10.6.8.6. Bahrain
    10.6.8.7. South Africa
    10.6.8.8. Egypt
    10.6.8.9. Nigeria
    10.6.8.10. Morocco
    10.6.8.11. Rest of Middle East & Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
11.4. Partner Identification Analysis
11.5. Investment & Funding Landscape
11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

12.1. Merck & Co., Inc.*
  12.1.1. Company Overview
  12.1.2. Product Portfolio
  12.1.3. Revenue Analysis
  12.1.4. Pricing Analysis
  12.1.5. SWOT Analysis
  12.1.6. Recent Developments
    12.1.6.1. Major Deals
    12.1.6.2. M&A
    12.1.6.3. Collaboration
    12.1.6.4. Acquisition
    12.1.6.5. Joint Ventures
    12.1.6.6. Innovations
  12.1.7. Recent News
    12.1.7.1. Events
    12.1.7.2. Conferences
    12.1.7.3. Symposiums
    12.1.7.4. Webinars
12.2. Zoetis Services LLC
12.3. Ceva.
12.4. Boehringer Ingelheim International GmbH
12.5. Elanco
12.6. Virbac
  12.6.1. Phibro Animal Health Corporation
12.7. Biog?nesis Bag?
12.8. Neogen Corporation
12.9. Bimeda Biologicals (LIST NOT EXHAUSTIVE)

13. GLOBAL VETERINARY VACCINES MARKET – RESEARCH METHODOLOGY

13.1. Research Data
  13.1.1. Secondary Data
  13.1.2. Primary Data
  13.1.3. CAGR Analysis
13.2. Market Size Estimation Methodology
  13.2.1. Bottom-Up Approach
  13.2.2. Top-Down Approach
13.3. Market Breakdown & Data Triangulation
13.4. Research Assumptions
13.5. Limitations

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us